MarkHubermanMD

PubMed

• 4 citations
  Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer.
  Joel W. Neal, Daniel B. Costa, Alona Muzikansky, Joseph B. Shrager, Michael Lanuti, James Huang, Kavitha J Ramachandran, Deepa Rangachari, Mark S. Huberman, Zofia Piot...> ;JCO Precision Oncology. 2021 Feb 1
• 12 citations
  Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer
  Kartik Sehgal, Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri, Danielle C. McDonald, Cynthia R. Cherry, Meghan Shea, Mark S. Hub...> ;Clinical Lung Cancer. 2021 May 1
• 1 citations
  Erratum: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas (Clinical Cancer Research (2018) 24 (6...
  Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu Kobayashi...> ;Clinical Cancer Research. 2020 May 1
• 18 citations
  EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
  Susan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R Oxnard, Deepa Rangachari, Mark S Huberman, Lecia V Sequist, Susumu S Kobayashi, D...> ;Clinical Cancer Research. 2018 Dec 15
• 51 citations
  Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.
  Zofia Piotrowska, Daniel B. Costa, Geoffrey R. Oxnard, Mark S. Huberman, Justin F. Gainor, Inga T. Lennes, Alona Muzikansky, Alice T. Shaw, Christopher G. Azzoli, Rebe...> ;Annals of Oncology. 2018 Oct 1
• 67 citations
  Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer
  Lorena Ostios-Garcia, Jennifer Faig, Giulia Costanza Leonardi, Anika E. Adeni, S. Subegdjo, Christine A. Lydon, Deepa Rangachari, Mark S. Huberman, Kartik Sehgal, Megh...> ;Journal of Thoracic Oncology. 2018 Jul 1
• 42 citations
  Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
  Paul A. VanderLaan, Deepa Rangachari, Adnan Majid, Mihir Parikh, Sidharta P. Gangadharan, Michael S. Kent, Danielle C. McDonald, Mark S. Huberman, Susumu Kobayashi, Da...> ;Lung Cancer. 2018 Jan 4
• 12 citations
  Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.
  Deepa Rangachari, Xiuning Le, Meghan Shea, Mark S. Huberman, Paul A. VanderLaan, Susumu Kobayashi, Daniel B. Costa> ;Journal of Thoracic Oncology. 2017 Nov 1
• 107 citations
  Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma
  Deepa Rangachari, Paul A. VanderLaan, Meghan Shea, Xiuning Le, Mark S. Huberman, Susumu Kobayashi, Daniel B. Costa> ;Journal of Thoracic Oncology. 2017 May 1
• 139 citations
  Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
  Paul A. VanderLaan, Deepa Rangachari, Susan M. Mockus, Vanessa Spotlow, Honey V. Reddi, Joan Malcolm, Mark S. Huberman, Loren Joseph, Susumu Kobayashi, Daniel B. Costa> ;Lung Cancer. 2017 Apr 1
• 38 citations
  EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.
  Yuri Sheikine, Deepa Rangachari, Danielle C. McDonald, Mark S. Huberman, Erik S. Folch, Paul A. VanderLaan, Daniel B. Costa> ;Clinical Lung Cancer. 2016 Nov 1
• 14 citations
  De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers
  Antonio R. Lucena-Araujo, Jason P. Moran, Paul A. VanderLaan, Dora Dias-Santagata, Erik Folch, Adnan Majid, Michael S. Kent, Sidharta P. Gangadharan, Deepa Rangachari,...> ;Lung Cancer. 2016 Sep 1
• 15 citations
  Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma
  Meghan Shea, Mark S. Huberman, Daniel B. Costa> ;Journal of Thoracic Oncology. 2016 Jul 1
• 5 citations
  Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma.
  Helen M. Shields, Justin W. Li, Stephen R. Pelletier, Helen H. Wang, Rachel A. Freedman, Harvey J. Mamon, Andrea K. Ng, Arnold S. Freedman, Steven E. Come, David Aviga...> ;Diseases of the Esophagus. 2016 Jun 1
• 28 citations
  Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas
  Daniel B. Costa, Susan E. Jorge, Jason P. Moran, Jason A. Freed, Jessica A. Zerillo, Mark S. Huberman, Susumu Kobayashi> ;Journal of Thoracic Oncology. 2016 Jun 1
• 7 citations
  Rapidly fatal advanced EGFR -mutated lung cancers and the need for rapid tumor genotyping in clinical practice
  Deepa Rangachari, Lauren Drake, Mark S. Huberman, Danielle C. McDonald, Paul A. VanderLaan, Erik Folch, Daniel B. Costa> ;Cancer Treatment Communications. 2016 Jan 1
• 60 citations
  Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping muta...
  Susan E. Jorge, Sol Schulman, Jason A. Freed, Paul A. VanderLaan, Deepa Rangachari, Susumu Kobayashi, Mark S. Huberman, Daniel B. Costa> ;Lung Cancer. 2015 Dec 1
• 7 citations
  Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
  Xiuning Le, Jason A. Freed, Paul A. VanderLaan, Mark S. Huberman, Deepa Rangachari, Susan E. Jorge, Antonio R. Lucena-Araujo, Susumu Kobayashi, Sohail Balasubramanian,...> ;Clinical Lung Cancer. 2015 Sep 1
• 323 citations
  Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
  Deepa Rangachari, Norihiro Yamaguchi, Paul A. VanderLaan, Erik Folch, Anand Mahadevan, Scott R. Floyd, Erik J. Uhlmann, Eric S. Wong, Suzanne E. Dahlberg, Mark S. Hube...> ;Lung Cancer. 2015 Apr 1
• 21 citations
  De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors
  Xiuning Le, Neelam V. DeSai, Adnan Majid, Rebecca Karp, Mark S. Huberman, Deepa Rangachari, Michael S. Kent, Sidhu P. Gangadharan, Erik Folch, Paul A. VanderLaan, Dani...> ;Lung Cancer. 2015 Apr 1
• 20 citations
  Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice
  Deepa Rangachari, Paul A. VanderLaan, Xiuning Le, Erik Folch, Michael S. Kent, Sidhu P. Gangadharan, Adnan Majid, Richard L. Haspel, Loren Joseph, Mark S. Huberman, Da...> ;Cancer Treatment Communications. 2015 Jan 1
• 109 citations
  Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer
  Paul A. VanderLaan, Norihiro Yamaguchi, Erik Folch, David Boucher, Michael S. Kent, Sidhu P. Gangadharan, Adnan Majid, Michael A. Goldstein, Mark S. Huberman, Olivier ...> ;Lung Cancer. 2014 Apr 1
• 387 citations
  Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer.
  Hiroyuki Yasuda, Eun Young Park, Cai Hong Yun, Natasha J. Sng, Antonio R. Lucena-Araujo, Wee-Lee Yeo, Mark S. Huberman, David W. Cohen, Sohei Nakayama, Kota Ishioka, N...> ;Science Translational Medicine. 2013 Dec 18
• 58 citations
  Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.
  Erik Folch, Norihiro Yamaguchi, Paul A. VanderLaan, Olivier Kocher, David Boucher, Michael A. Goldstein, Mark S. Huberman, Michael S. Kent, Sidharta P. Gangadharan, Da...> ;Journal of Thoracic Oncology. 2013 Nov 1
• 47 citations
  Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academi...
  Norihiro Yamaguchi, Paul A. VanderLaan, Erik Folch, David Boucher, Hannah M. Canepa, Michael S. Kent, Sidhu P. Gangadharan, Adnan Majid, Olivier Kocher, Michael A. Gol...> ;Lung Cancer. 2013 Oct 1
• Join now to see all